Hansen Medical Announces Publication of Uterine Artery Embolization (UAE) Results

MOUNTAIN VIEW, CA--(Marketwired - Jul 29, 2014) - Hansen Medical, Inc. (NASDAQ: HNSN) -- A study, published online in the Journal of Vascular Interventional Radiology, found the use of the Magellan Robotic System in uterine artery embolization, or "UAE", procedures is feasible and appears to be safe. Researchers reviewed the results of five patients treated with robot-assisted UAE over a 10 month period at St. Mary's Hospital, Imperial College London. Lead Investigator Dr. Mohammad Hamady and his colleagues conducted the study to investigate the safety and feasibility of the Magellan 9Fr Robotic Catheter in this complex arterial bed.

All procedures were successfully completed without local puncture site complications or access vessel injuries. Further, robotic bilateral internal iliac artery cannulation was successfully performed in all cases. At the six-month follow-up mark, all patients reported significant improvement in symptoms and quality-of-life.

"We are very pleased with the results of the Magellan Robotic System in UAE procedures, and appreciate the work of the investigators at Imperial College London," said Cary Vance, President and CEO of Hansen Medical. "The findings from this study highlight the potential in women's health, and we expect that a broad group of patients will be able to benefit from robot assisted embolization procedures."

Uterine fibroids are tumors that grow in a woman's womb. They are the most common benign tumors in women and the leading cause for hysterectomies in the US. As many as 1 in 5 women may have fibroids during their childbearing years. Half of all women have fibroids by age 50. Uterine artery embolization is a minimally-invasive treatment option for uterine fibroids in which a catheter is used to deliver small particles into the uterine artery to stop blood flow to the fibroids.

"This study provides an initial foundation for this clinical application of intravascular robotics," said Dr. Hamady, Imperial College London. "The use of robotic catheters in UAE procedures offer several potential benefits. Fine adjustments can be made to the catheter tip, which may improve predictability of navigation in complex anatomy."

About the Magellan™ Robotic System
Hansen Medical's (NASDAQ: HNSN) Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver improved predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the U.S. and Europe. The Magellan Robotic System offers several important features including: